clinical trial · NCT06441084
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
Nuwacell Biotechnologies Co., Ltd.·phase1·not yet recruiting·n = 15
Acute Myeloid LeukemiaNCR300 injection
brief summary
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
started
Jun 30, 2024
primary completion
Dec 31, 2028
completion
Dec 31, 2031
last updated
Jun 4, 2024
detailed description
This is an open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability and preliminary efficacy of NCR300 injection.
official title
A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol